Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SGEN

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest

Seagen Chief Executive Clay Siegall resigned Monday amid domestic violence allegations, and SGEN stock inched up.

Investors Business Daily

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

The Board of Directors of Seagen Inc (NASDAQ:SGEN) announced that its long-time president, CEO, and chairman Clay Siegall, is on a leave of absence. The move follows an alleged incident of domestic violence. While Siegall, who informed the company that he's in the middle of a divorce, denied those allegations. The Seagen board…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim

Seagen CEO Clay Siegall was placed on leave after a domestic abuse allegation, the biotech company said Monday as SGEN stock dropped.

Investors Business Daily

Looking Into Seattle Genetics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49 million.

Expert Ratings for Seagen

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Seagen Q1 Earnings

Recap: Seagen Q1 Earnings

Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by 26.0%, reporting an EPS of $-0.74 versus an estimate of $-1.0.

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF)

What 7 Analyst Ratings Have To Say About Seagen

What 7 Analyst Ratings Have To Say About Seagen

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter:

How An AstraZeneca Rivalry Led Seagen Stock To Crumble Despite A Sales Beat

How An AstraZeneca Rivalry Led Seagen Stock To Crumble Despite A Sales Beat

Seagen offered a disappointing outlook for 2022 as AstraZeneca pressures its new breast cancer drug, leading SGEN stock to dive on Thursday.

Investors Business Daily

Looking Into Seattle Genetics's Return On Capital Employed

Looking Into Seattle Genetics's Return On Capital Employed

According to data from Benzinga Pro, during Q4, Seattle Genetics's (NASDAQ:SGEN) reported sales totaled $429.85 million. Despite a 40.57% increase in earnings, the company posted a loss of $174.63 million.

Why Are Seagen Shares Sinking Today?

Why Are Seagen Shares Sinking Today?

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: Seagen Q4 Earnings

Seagen (NASDAQ:SGEN) reported its Q4 earnings results on Wednesday, February 9, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Seagen missed estimated earnings by 15.85%, reporting an EPS of $-0.95 versus an estimate of $-0.82.

Will Chart Analysts Notice Bad Omen on Seagen's Chart

If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer

Seagen Inc (NASDAQ: SGEN)

Where Seagen Stands With Analysts

Within the last quarter, Seagen (NASDAQ: SGEN) has observed the following analyst ratings: Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Board of Directors

RBC Capital Markets

Astellas Pharma Inc

Roche Holdings AG

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

domestic violence

Places

290,266 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play